The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

Recursion Pharmaceuticals (RXRX) closed the latest trading day at $5.41, indicating a -1.64% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...